Selecting between anti-CD20 bispecific antibodies and anti-CD19 CAR T-cells in third-line NHL 

Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, discusses the role of anti-CD20 bispecific antibodies in treating non-Hodgkin lymphoma (NHL) and their sequencing with anti-CD19 CAR T-cells. Both are approved for third-line therapy. Dr Kamdar usually selects CAR T-cells in this setting due to longer follow-up data, proven central nervous system (CNS) efficacy, and concerns that using bispecific antibodies first might lead to T-cell exhaustion, reducing the effectiveness of subsequent CAR T-cell treatment. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.